Spots Global Cancer Trial Database for ras mutation

Every month we try and update this database with for ras mutation cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.

The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Safety and Effectiveness of ABM-168 in Adults With Advanced Solid Tumors.	NCT05831995	Advanced Solid ... RAS Mutation RAF Mutation NF1 Mutation	ABM-168	18 Years -	ABM Therapeutics Corporation
Centralized Tumour Board and Secondary Intervention Rate in mCRC	NCT04852250	Metastatic Colo... RAS Mutation Multidisciplina... Secondary Inter...	Virtual central...	18 Years -	Ludwig-Maximilians - University of Munich
RASopathy Biorepository	NCT04395495	RAS Mutation Neurofibromatos... Noonan Syndrome Noonan Syndrome... Noonan Neurofib... Cardiofaciocuta... Costello Syndro... Legius Syndrome Smith-Kingsmore... MTOR Gene Mutat... GATOR-1 Gene Mu... SYNGAP1-Related... DLG4 MAPK1 Gene Muta...		-	Children's Hospital Medical Center, Cincinnati
Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations	NCT06229340	RAS Mutation Ras (Kras or Nr... Colorectal Canc... Pancreas Cancer Lung Cancer Melanoma Refractory Canc...	Leflunomide The combination...	18 Years - 85 Years	N.N. Petrov National Medical Research Center of Oncology
PF-07284892 in Participants With Advanced Solid Tumors	NCT04800822	Solid Tumor	PF-07284892 lorlatinib binimetinib cetuximab encorafenib	18 Years -	Pfizer
Study of RAS(ON) Inhibitor Combinations in Patients With Advanced RAS-mutated NSCLC	NCT06162221	Non-Small Cell ... KRAS, NRAS, HRA... KRAS G12C-mutat... Lung Cancer Sta...	RMC-6291 RMC-6236 Pembrolizumab Cisplatin Carboplatin Pemetrexed	18 Years -	Revolution Medicines, Inc.
Study of RAS(ON) Inhibitor Combinations in Patients With Advanced RAS-mutated NSCLC	NCT06162221	Non-Small Cell ... KRAS, NRAS, HRA... KRAS G12C-mutat... Lung Cancer Sta...	RMC-6291 RMC-6236 Pembrolizumab Cisplatin Carboplatin Pemetrexed	18 Years -	Revolution Medicines, Inc.
Cadonilimab in Combination With Bevacizumab and FOLFOX Regimen for the First-Line Treatment of Advanced Unresectable MSS-Type, RAS-Mutated Metastatic Colorectal Cancer	NCT06218810	Metastatic Colo... Microsatellite ... RAS Mutation Cadonilimab	Cadonilimab + b...	18 Years - 75 Years	Fudan University
A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies	NCT04678648	Advanced Malign... RAS Mutation Lung Cancer Colon Cancer Glioblastoma Pancreatic Canc...	RSC-1255 Dose E... RSC-1255 Dose E...	18 Years -	RasCal Therapeutics, Inc.
RAS Mutation Testing in the Circulating Blood of Patients With Metastatic Colorectal Cancer	NCT02502656	Colorectal Canc...		18 Years -	Association des Gastroentérologues Oncologues
Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations	NCT06229340	RAS Mutation Ras (Kras or Nr... Colorectal Canc... Pancreas Cancer Lung Cancer Melanoma Refractory Canc...	Leflunomide The combination...	18 Years - 85 Years	N.N. Petrov National Medical Research Center of Oncology
NAUTILUS: OKI-179 Plus Binimetinib in Patients With Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2)	NCT05340621	RAS Mutation NRAS Gene Mutat... Melanoma	OKI-179 + binim...	18 Years -	OnKure, Inc.
Leflunomide or Combination of MEK Inhibitor and Hydroxychloroquine for Refractory Patients With RAS Mutations	NCT06229340	RAS Mutation Ras (Kras or Nr... Colorectal Canc... Pancreas Cancer Lung Cancer Melanoma Refractory Canc...	Leflunomide The combination...	18 Years - 85 Years	N.N. Petrov National Medical Research Center of Oncology
Sintilimab (IBI308) Combined With Bevacizumab + XELOX Regimen in Metastatic Colorectal Cancer	NCT04194359	Metastatic Colo... RAS Mutation Microsatellite ...	Sintilimab (IBI...	18 Years - 75 Years	Second Affiliated Hospital, School of Medicine, Zhejiang University
FOLFOXIRI With or Without Bevacizumab as First-line Treatment for Unresectable Liver-only Metastatic Colorectal Cancer Patients With RAS Mutation-type	NCT02350530	Metastatic Colo...	FOLFOXIRI + Bev... FOLFOXIRI	18 Years - 70 Years	Sun Yat-sen University
RASopathy Biorepository	NCT04395495	RAS Mutation Neurofibromatos... Noonan Syndrome Noonan Syndrome... Noonan Neurofib... Cardiofaciocuta... Costello Syndro... Legius Syndrome Smith-Kingsmore... MTOR Gene Mutat... GATOR-1 Gene Mu... SYNGAP1-Related... DLG4 MAPK1 Gene Muta...		-	Children's Hospital Medical Center, Cincinnati
Safety and Effectiveness of ABM-168 in Adults With Advanced Solid Tumors.	NCT05831995	Advanced Solid ... RAS Mutation RAF Mutation NF1 Mutation	ABM-168	18 Years -	ABM Therapeutics Corporation
PAS-004 in Patients With Advanced Solid Tumors	NCT06299839	RAS Mutation NF1 Mutation RAF Mutation Advanced Solid ...	PAS-004	18 Years -	Pasithea Therapeutics Corp.
PF-07284892 in Participants With Advanced Solid Tumors	NCT04800822	Solid Tumor	PF-07284892 lorlatinib binimetinib cetuximab encorafenib	18 Years -	Pfizer
The Emergence of RAS Mutations in Metastatic Colorectal Cancer Patients Receiving Cetuximab Treatment	NCT03401957	Colorectal Canc... Drug Resistance Mass Spectromet... RAS-RAF Pathway...	Cetuximab liquid biopsy	20 Years - 90 Years	National Health Research Institutes, Taiwan
PAS-004 in Patients With Advanced Solid Tumors	NCT06299839	RAS Mutation NF1 Mutation RAF Mutation Advanced Solid ...	PAS-004	18 Years -	Pasithea Therapeutics Corp.

Take Control of Your Skin and Body Changes Today.

Try out Spots for free, set up only takes 2 mins.

Join others from around the world: